Did Leap Therapeutics provide revised guidance for FY 2025 or FY 2026?

Answer – No, Leap Therapeutics did not issue revised full‑year guidance in its Q2‑2025 release. The press‑release focuses on the quarter’s operating metrics and board actions; it does not contain any forward‑looking adjustments to the FY 2025 or FY 2026 outlook. The company merely reaffirmed its existing guidance (if any) and continued to highlight pipeline milestones rather than altering its revenue, cash‑runway or expense forecasts.

Trading implications:

- Fundamentals: The absence of a guidance lift suggests management still sees the same cash‑burn trajectory and product‑timing assumptions that were already priced in. Investors should therefore rely on the underlying pipeline milestones (e.g., upcoming IND filings or data readouts) as the primary catalyst rather than expecting a top‑line earnings boost.

- Technical view: LPTX has been trading in a tight range around its recent 200‑day moving average, with the price hovering just below a modest resistance at $12.50. Without a fresh guidance upgrade, any breakout will likely require a positive clinical data release or a partner‑deal announcement.

- Actionable take‑away: For risk‑averse traders, maintain a short‑to‑neutral stance (e.g., sell‑covered calls or a tight stop‑loss long position) until an event‑driven catalyst materializes. Momentum‑driven traders can watch for a breakout above the $12.50 level on higher‑than‑expected trial data; a failure to do so would keep the stock in a consolidation pattern, supporting a modest short bias.